Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

 Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:

  • Indivumed to receive upfront from Evotec, for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be responsible for upcoming partnering for the program/platform
  • The focus of the agreement is to develop precision therapies for CRC patients with the combination of Evotec’s bioinformatics analysis platform “PanHunter” with CRC cohort of Indivumed’s IndivuType  
  • IndivuType is a multi-omics database for personalized cancer therapies that allows identification of the novel targets and biomarkers enabling break-through insights that lead to new cancer solutions

Click here to read full press release/ article | Ref: Evotec | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post